Atorvastatin/glimepiride

Drug Profile

Atorvastatin/glimepiride

Alternative Names: Glimepiride/atorvastatin

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrroles; Sulfones; Sulfonylureas
  • Mechanism of Action HMG-CoA reductase inhibitors; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top